Syndax Pharmaceuticals Inc (SNDX) - Net Assets

Latest as of March 2026: $41.62 Million USD

Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has net assets worth $41.62 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($472.67 Million) and total liabilities ($431.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Syndax Pharmaceuticals Inc's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$41.62 Million
% of Total Assets	8.81%
Annual Growth Rate	N/A
5-Year Change	-84.17%
10-Year Change	-23.19%
Growth Volatility	214.55

Syndax Pharmaceuticals Inc - Net Assets Trend (2011–2025)

This chart illustrates how Syndax Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See Syndax Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Syndax Pharmaceuticals Inc (2011–2025)

The table below shows the annual net assets of Syndax Pharmaceuticals Inc from 2011 to 2025. For live valuation and market cap data, see SNDX market cap overview.

Year	Net Assets	Change
2025-12-31	$64.63 Million	-77.57%
2024-12-31	$288.12 Million	-48.01%
2023-12-31	$554.20 Million	+18.56%
2022-12-31	$467.45 Million	+14.47%
2021-12-31	$408.37 Million	+61.93%
2020-12-31	$252.19 Million	+698.06%
2019-12-31	$31.60 Million	-40.43%
2018-12-31	$53.05 Million	-49.15%
2017-12-31	$104.32 Million	+23.98%
2016-12-31	$84.14 Million	+26.15%
2015-12-31	$66.70 Million	+1266.86%
2014-12-31	$-5.72 Million	-148.24%
2013-12-31	$11.85 Million	+140.46%
2012-12-31	$-29.29 Million	-53.70%
2011-12-31	$-19.05 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Syndax Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 143768000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	$9.00K	0.01%
Other Comprehensive Income	$452.00K	0.70%
Other Components	$1.57 Billion	2430.37%
Total Equity	$64.63 Million	100.00%

Syndax Pharmaceuticals Inc Competitors by Market Cap

The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their market capitalization.

Company	Market Cap
Bank Ocbc Nisp Tbk JK:NISP	$1.69 Billion
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	$1.69 Billion
UIE PLC CO:UIE	$1.69 Billion
The Baldwin Insurance Group, Inc. NASDAQ:BWIN	$1.69 Billion
Australian United Investment Company Ltd AU:AUI	$1.69 Billion
Makalot Industrial Co Ltd TW:1477	$1.69 Billion
Banpu Public Company Limited BK:BANPU	$1.69 Billion
Fufeng Group Limited F:FFO1	$1.69 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Syndax Pharmaceuticals Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 288,124,000 to 64,630,000, a change of -223,494,000 (-77.6%).
Net loss of 285,422,000 reduced equity.
Other comprehensive income increased equity by 289,000.
Other factors increased equity by 61,639,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-285.42 Million	-441.62%
Other Comprehensive Income	$289.00K	+0.45%
Other Changes	$61.64 Million	+95.37%
Total Change	$-	-77.57%

Book Value vs Market Value Analysis

This analysis compares Syndax Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 25.52x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	$0.00	$19.04	x
2012-12-31	$-0.42	$19.04	x
2013-12-31	$1.48	$19.04	x
2014-12-31	$-0.60	$19.04	x
2015-12-31	$11.93	$19.04	x
2016-12-31	$5.76	$19.04	x
2017-12-31	$4.97	$19.04	x
2018-12-31	$2.09	$19.04	x
2019-12-31	$1.04	$19.04	x
2020-12-31	$6.11	$19.04	x
2021-12-31	$7.84	$19.04	x
2022-12-31	$7.69	$19.04	x
2023-12-31	$7.88	$19.04	x
2024-12-31	$3.37	$19.04	x
2025-12-31	$0.75	$19.04	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Syndax Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -441.62%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -165.60%
• Asset Turnover: 0.33x
• Equity Multiplier: 8.20x
Recent ROE (-441.62%) is below the historical average (-81.80%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	0.00%	0.00%	0.00x	0.00x	$-11.18 Million
2012	0.00%	0.00%	0.00x	0.00x	$-7.04 Million
2013	-119.60%	0.00%	0.00x	1.44x	$-15.36 Million
2014	0.00%	0.00%	0.00x	0.00x	$-19.26 Million
2015	-36.16%	-3846.73%	0.01x	1.35x	$-30.79 Million
2016	-52.86%	-3645.25%	0.01x	1.30x	$-52.89 Million
2017	-58.28%	-2884.35%	0.02x	1.32x	$-71.23 Million
2018	-139.43%	-4875.48%	0.02x	1.58x	$-79.27 Million
2019	-177.07%	-3688.53%	0.02x	2.01x	$-59.12 Million
2020	-28.97%	-4816.68%	0.01x	1.19x	$-98.29 Million
2021	6.10%	17.84%	0.31x	1.10x	$-15.91 Million
2022	-30.75%	-113.57%	0.25x	1.06x	$-190.49 Million
2023	-37.78%	0.00%	0.00x	1.11x	$-264.78 Million
2024	-110.63%	-1346.11%	0.03x	2.52x	$-347.57 Million
2025	-441.62%	-165.60%	0.33x	8.20x	$-291.88 Million

Industry Comparison

This section compares Syndax Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $155,285,360
Average return on equity (ROE) among peers: -101.11%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Syndax Pharmaceuticals Inc (SNDX)	$41.62 Million	0.00%	10.36x	$1.69 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-34.80 Million	0.00%	0.00x	$83.17 Million
Abcellera Biologics Inc (ABCL)	$830.51 Million	14.32%	0.21x	$1.61 Billion
Abeona Therapeutics Inc (ABEO)	$-26.99 Million	0.00%	0.00x	$321.39 Million
Acumen Pharmaceuticals Inc (ABOS)	$266.97 Million	-19.62%	0.16x	$155.29 Million
Abpro Holdings, Inc. (ABP)	$3.07 Million	-479.81%	1.57x	$2.00 Million
Absci Corp (ABSI)	$179.13 Million	-57.56%	0.19x	$1.01 Billion
Arbutus Biopharma Corp (ABUS)	$182.50 Million	-46.25%	0.30x	$831.63 Million
ABVC Biopharma Inc (ABVC)	$4.59 Million	-357.76%	1.38x	$35.10 Million
Abivax SA American Depositary Shares (ABVX)	$33.94 Million	-14.97%	0.12x	$7.98 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$113.93 Million	-49.49%	0.18x	$3.66 Billion

About Syndax Pharmaceuticals Inc

NASDAQ:SNDX USA Biotechnology

Market Cap

$1.69 Billion

Market Cap Rank

#6903 Global

#2071 in USA

Share Price

$19.04

Change (1 day)

+2.64%

52-Week Range

$8.73 - $25.15

All Time High

$28.98